Results 131 to 140 of about 2,147 (178)

Cardiac sarcoidosis: from clinical manifestations to heart transplantation. [PDF]

Front Med (Lausanne)
Starshinova A, Fedotov P, Bulgun M, Kudryavtsev I, Rubinstein A, Aquino AD, Kudlay D, Shlyakhto E.   +7 more
europepmc   +1 more source

Comparative Efficacy and Safety of Colchicine and Anti-Interleukin-1 Agents in Recurrent Pericarditis: A Pairwise and Network Meta-Analysis of Randomized Controlled Trials. [PDF]

J Am Heart Assoc
Ehsan M, Syed AB, Mustafa B, Ikram J, Khan MH, Cremer PC, Imazio M, Wang TKM, Klein AL.   +8 more
europepmc   +1 more source

Autoimmune Pericarditis: Diagnosis and New Therapeutics. [PDF]

Curr Cardiol Rep
Wassif H, Ghandakly E, Layoun H, Bhalla JS, Littlejohn E, Wang TKM, Husni E, Klein A.   +7 more
europepmc   +1 more source

Rilonacept in Refractory Immune Checkpoint Inhibitor-Induced Recurrent Pericarditis: A Potential Treatment Option. [PDF]

JACC Case Rep
Patel H, Thangjui S, Watson H, Balla S.
europepmc   +1 more source

Schnitzler syndrome - a rare cause of chronic urticaria. Case report. [PDF]

Oxf Med Case Reports
Moos Ł, Kułakowska A, Szydłowska D, Chodak W, Brzoza Z.   +4 more
europepmc   +1 more source

Subacromial bursitis: current evidence and future directions in injection-based therapies-A narrative review. [PDF]

Ann Med
Ding J, Liu S, Jiang P, Jiang H, Han F, Qu W.   +5 more
europepmc   +1 more source

Successful Management of Recurrent Pericarditis with Rilonacept in a Young Adult

Aung, Thanda, McMahon, Maureen
openaire   +1 more source

Rilonacept—CAPS and Beyond

Annals of the New York Academy of Sciences, 2009
Rilonacept is a dimeric fusion protein consisting of the extracellular domains of interleukin (IL)‐1 type 1 receptor and IL‐1 receptor accessory protein joined to the constant region (Fc) of human immunoglobulin G1. By incorporating both components of the IL‐1 binding complex, rilonacept is able to tightly bind IL‐1 with picomolar affinity.
Neil Stahl, Allen Radin, Scott Mellis
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Rilonacept for the treatment of recurrent pericarditis

Expert Opinion on Biological Therapy, 2022
Recurrent pericarditis (RP) is a debilitating disease that has an underlying autoinflammatory pathophysiology mediated by cytokine interleukin (IL)-1. Rilonacept, a recombinant dimeric fusion protein that blocks IL-1α and IL-1β signaling has emerged as a valuable therapeutic option of RP.
Reza Reyaldeen, Emmanuel Akintoye
exaly   +3 more sources